PR Newswire Clinical TrialsOriginal article
Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)
Phase 2YA-101Positive
AI Analysis
Summary
Dasher Neuroscience completed patient enrollment in a Phase 2 global clinical trial of YA-101, its lead AI drug candidate for Multiple System Atrophy. The enrollment milestone represents progress toward potential efficacy and safety data readout.
Clinical Trial Data
Phase
Phase 2
Outcome Details
Patient enrollment completed
Importance:6/10
Sentiment:
0.60
Phase 2CNSAI-driven drug discoveryenrollment completionneurological disorder
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 28, 2026 12:12 PM